Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial.
OBJECTIVE
To compare live birth rates in women with recurrent pregnancy loss (RPL) and either autoantibodies or a coagulation abnormality, treated with low molecular weight heparin plus aspirin (LMWH/ASA) or ASA alone, and to place our results in context with other randomized clinical trials (RCT) with similar cohorts.


METHODS
The HepASA Trial was an RCT including patients with a history of RPL and at least 1 of the following: antiphospholipid antibody (aPL), an inherited thrombophilia, or antinuclear antibody. Treatment groups were stratified by aPL status and history of early versus late pregnancy losses. Patients received either LMWH/ASA or ASA alone. The primary outcome was live birth; secondary outcomes included adverse events and bone loss at the spine and femoral neck. Literature over the past 20 years was reviewed to identify comparable RCT.


RESULTS
Over 4 years, 859 women with RPL were screened: 88 (10.2%) fulfilled inclusion criteria, became pregnant and were randomized to receive either LMWH/ASA or ASA alone. aPL were present in 42 (47.7%) patients in each group. The trial was stopped after 4 years when an interim analysis showed no difference in live birth rates in the 2 groups, and a lower rate of pregnancy loss in the ASA only group than expected. In the LMWH/ASA group, 35/45 (77.8%) had a live birth versus 34/43 (79.1%) in the ASA only group (p = 0.71). Neither number of prior losses nor aPL status was correlated with pregnancy outcome. There were no cases of pregnancy related thrombosis in either group. Mean change in BMD did not differ by treatment group at either the lumbar spine (p = 0.57) or femoral neck (p = 0.15). RCT since 2000 for aPL positive women with RPL and similar inclusion criteria report a mean live birth rate of 75% with either LMWH or ASA.


CONCLUSIONS
LMWH/ASA did not confer incremental benefit compared to ASA alone for this population. Regardless of treatment regimen, number of prior losses, or aPL positivity, almost 80% of women in our RPL cohort had a successful pregnancy outcome. These findings contribute to a growing body of literature that contests the emerging standard of care comprising LMWH/ASA for this population.
Laskin
Carl A
CA
University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, Canada.
Spitzer
Karen A
KA
Clark
Christine A
CA
Crowther
Mark R
MR
Ginsberg
Jeff S
JS
Hawker
Gillian A
GA
Kingdom
John C
JC
Barrett
Jon
J
Gent
Michael
M
D000026:Abortion, Habitual / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D000328:Adult; D000974:Antibodies, Antinuclear / Q000276:immunology; D000925:Anticoagulants / Q000008:administration & dosage; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D001241:Aspirin / Q000008:administration & dosage*; D001327:Autoimmune Diseases / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D001778:Blood Coagulation Disorders / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D015519:Bone Density / Q000187:drug effects; D015331:Cohort Studies; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D019851:Thrombophilia / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D016896:Treatment Outcome
D000974:Antibodies, Antinuclear; D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin